公开(公告)号：US20180092901A1

公开(公告)日：2018-04-05

申请号：US15554577

申请日：2016-03-03

Applicant: MERCK SHARP & DOHME CORP. ,  Eisai R&D Management Co., Ltd.

Inventor： Andrew Evan DENKER ,  Yu KATO ,  Kimiyo TABATA ,  Yusaku HORI

IPC: A61K31/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: A61K31/47 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/76

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

公开(公告)号：US20230330081A1

公开(公告)日：2023-10-19

申请号：US18030207

申请日：2021-10-26

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Taisuke HOSHI ,  Yu KATO ,  Yoichi OZAWA ,  Satoshi KAWANO ,  Kotaro KODAMA ,  Saori MIYANO

IPC: A61K31/4545 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61P35/00 ,  A61K2039/505

Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.

公开(公告)号：US20220409724A1

公开(公告)日：2022-12-29

申请号：US17772468

申请日：2020-10-28

Applicant: Eisai R&D Management Co., Ltd. ,  Merck Sharp & Dohme Corp. ,  MSD International GmbH

Inventor： Yoichi OZAWA ,  Yasuhiro FUNAHASHI ,  Yu KATO

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/47 ,  A61K31/53

Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.

公开(公告)号：US20220023285A1

公开(公告)日：2022-01-27

申请号：US17502962

申请日：2021-10-15

Applicant: MERCK SHARP & DOHME CORP. ,  EISAI R&D MANAGEMENT CO., LTD.

Inventor： Andrew Evan DENKER ,  Yu KATO ,  Kimiyo TABATA ,  Yusaku HORI

IPC: A61K31/47 ,  A61K39/395 ,  A61P35/00

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.